PsychonautWiki Archive

Mirtazapine: Difference between revisions

← Older editNewer edit →
>Blackhole
added brand name
>Xiaogongju
m citation
Line 1: Line 1:
{{SummarySheet}}
{{SummarySheet}}
{{SubstanceBox/Mirtazapine}}
{{SubstanceBox/Mirtazapine}}
'''Mirtazapine''' (trade name '''Remeron''' and '''Mirta TAD''', among others) is an [[psychoactive class::antidepressant]] substance of the [[Chemical class::piperazinoazepine]] class. At high doses, it has been reported to act as an atypical [[psychedelic]] and [[sedative]]. It is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA).{{citation needed}}
'''Mirtazapine''' (trade name '''Remeron''', among others) is an [[psychoactive class::antidepressant]] substance of the [[Chemical class::piperazinoazepine]] class. At high doses, it has been reported to act as an atypical [[psychedelic]] and [[sedative]]. It is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA).<ref>Roland A. Carlstedt (14 December 2009). ''Handbook of Integrative Clinical Psychology, Psychiatry, and Behavioral Medicine: Perspectives, Practices, and Research''. Springer Publishing Company. p. 290. [[ISBN (identifier)|ISBN]] [[Special:BookSources/978-0-8261-1094-7|<bdi>978-0-8261-1094-7</bdi>]]. Retrieved 23 April 2012.</ref>


Mirtazapine was developed in the Netherlands and introduced in the United States in 1996.<ref> "REMERON (mirtazapine) tablet, film coated [Organon Pharmaceuticals USA]". DailyMed. Organon Pharmaceuticals USA. October 2012. Retrieved 24 October 2013.</ref> Its patent expired in 2004 and generic versions have been widely available since.<ref name="Schatzberg">{{cite book | vauthors=((Schatzberg, A. F.)), ((Cole, J. O.)), ((DeBattista, C.)) | date= 2010 | title=Manual of clinical psychopharmacology | publisher=American Psychiatric Pub | volume=3 | edition=7th ed | isbn=9781585623778}}</ref> It is used primarily in the treatment of major depressive disorder and other mood disorders.<ref>{{cite journal | vauthors=((Gorman, J. M.)) | journal=The Journal of Clinical Psychiatry | title=Mirtazapine: clinical overview | volume=60 Suppl 17 | pages=9–13; discussion 46-48 | date= 1999 | issn=0160-6689}}</ref><ref>{{cite journal | journal=Expert Opinion on Pharmacotherapy | title=Review of the use of mirtazapine in the treatment of depression | url=https://informahealthcare.com/doi/abs/10.1517/14656566.2011.585459}}</ref> It has also been prescribed off-label for the treatment of  
Mirtazapine was developed in the Netherlands and introduced in the United States in 1996.<ref> "REMERON (mirtazapine) tablet, film coated [Organon Pharmaceuticals USA]". DailyMed. Organon Pharmaceuticals USA. October 2012. Retrieved 24 October 2013.</ref> Its patent expired in 2004 and generic versions have been widely available since.<ref name="Schatzberg">{{cite book | vauthors=((Schatzberg, A. F.)), ((Cole, J. O.)), ((DeBattista, C.)) | date= 2010 | title=Manual of clinical psychopharmacology | publisher=American Psychiatric Pub | volume=3 | edition=7th ed | isbn=9781585623778}}</ref> It is used primarily in the treatment of major depressive disorder and other mood disorders.<ref>{{cite journal | vauthors=((Gorman, J. M.)) | journal=The Journal of Clinical Psychiatry | title=Mirtazapine: clinical overview | volume=60 Suppl 17 | pages=9–13; discussion 46-48 | date= 1999 | issn=0160-6689}}</ref><ref>{{cite journal | journal=Expert Opinion on Pharmacotherapy | title=Review of the use of mirtazapine in the treatment of depression | url=https://informahealthcare.com/doi/abs/10.1517/14656566.2011.585459}}</ref> It has also been prescribed off-label for the treatment of  
Line 50: Line 50:


{{Preamble/SubjectiveEffects}}
{{Preamble/SubjectiveEffects}}
{{effects/base
{{effects/base
|{{effects/physical|
|{{effects/physical|
Line 64: Line 63:
*'''[[Effect::Bronchodilation]]''' - This can cause swallowing to be extremely difficult and uncomfortable, as with some other [[deliriants|anticholinergics]] such as [[diphenhydramine]]. As with [[diphenhydramine]], it is most prominent during the onset phase of the experience and often fades away as the peak sets in.
*'''[[Effect::Bronchodilation]]''' - This can cause swallowing to be extremely difficult and uncomfortable, as with some other [[deliriants|anticholinergics]] such as [[diphenhydramine]]. As with [[diphenhydramine]], it is most prominent during the onset phase of the experience and often fades away as the peak sets in.
*'''[[Effect::Muscle relaxation]]'''
*'''[[Effect::Muscle relaxation]]'''
*'''[[Effect::Restless legs]]''' - This effect is considered slightly less apparent than it is with [[diphenhydramine]] but more apparent than other atypical antidepressants like Trazadone or Doxepin.
*'''[[Effect::Restless legs]]''' - This effect is considered slightly less apparent than it is with [[diphenhydramine]].
*'''[[Effect::Nausea suppression]]'''
*'''[[Effect::Nausea suppression]]'''
}}
}}
Line 164: Line 163:
*[http://www.erowid.org/pharms/mirtazapine/mirtazapine.shtml Mirtazapine (Erowid Vault)]
*[http://www.erowid.org/pharms/mirtazapine/mirtazapine.shtml Mirtazapine (Erowid Vault)]
*[https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=9430 Mirtazapine (Isomer Design)]
*[https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=9430 Mirtazapine (Isomer Design)]
*[https://go.drugbank.com/drugs/DB00370 Mirtazapine (DrugBank)]
*[http://www.drugs.com/mirtazapine.html Mirtazapine (Drugs.com)]
*[http://www.drugs.com/mirtazapine.html Mirtazapine (Drugs.com)]


Retrieved from "http://psy.st/wiki/Mirtazapine"